Biomarker translational centre
At the Human Proteome Organization (HUPO) 2011 World Congress, in Switzerland, Thermo Fisher Scientific has announced the establishment of a biomarker translational centre.
At the Human Proteome Organization (HUPO) 2011 World Congress, in Switzerland, Thermo Fisher Scientific has announced the establishment of a biomarker translational centre. According to the company the centre will accelerate mass spectrometry (MS)-based biomarker discovery research and its translation into the development of routine clinical assays for subsequent commercialization. Based in Cambridge, Massachusetts, USA, the centre combines expertise from across the company including its B·R·A·H·M·S product line and the team at the company’s Biomarkers Research Initiatives in Mass Spectrometry (BRIMS) centre.
“Through the vertical integration with the unique talent in MS-based biomarker discovery and high-throughput quantitative assay development at BRIMS, we aim to expand our pipeline of new protein and peptide biomarkers with potential as clinical assays,” said Bruno Darbouret, director of research and development for B·R·A·H·M·S Biomarkers at the company. “Ultimately, this development effort will speed the commercialization of diagnostic tests that address life threatening diseases.”
The centre will investigate quantitative MS biomarker discovery and multiplexed selected reaction monitoring (SRM) assay development to identify putative biomarkers and their clinically relevant isoforms. It will also aim to develop robust, reproducible, targeted MS-based assays appropriate for the validation of putative biomarkers and ultimately for the clinical diagnostics market.
“Efficient translation of MS-based biomarker discovery research into the development of routine clinical diagnostic assays is an important challenge in the field of personalized medicine,” said Bryan Krastins, group leader at the centre. “Bridging this gap requires high-level competence in MS-based biomarker discovery and routine assay development for biomarker verification and validation. The new centre integrates all the capabilities needed to speed the clinical assay development pipeline from biomarker discovery to clinical assay development and validation.”
For more information about the company visit www.thermoscientific.com/ms
The Next Frontier for Mass Spectrometry: Maximizing Ion Utilization
January 20th 2025In this podcast, Daniel DeBord, CTO of MOBILion Systems, describes a new high resolution mass spectrometry approach that promises to increase speed and sensitivity in omics applications. MOBILion recently introduced the PAMAF mode of operation, which stands for parallel accumulation with mobility aligned fragmentation. It substantially increases the fraction of ions used for mass spectrometry analysis by replacing the functionality of the quadrupole with high resolution ion mobility. Listen to learn more about this exciting new development.
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Testing Solutions for Metals and PFAS in Water
January 22nd 2025When it comes to water analysis, it can be challenging for labs to keep up with ever-changing testing regulations while also executing time-efficient, accurate, and risk-mitigating workflows. To ensure the safety of our water, there are a host of national and international regulators such as the US Environmental Protection Agency (EPA), World Health Organization (WHO), and the European Union (EU) that demand stringent testing methods for drinking water and wastewater. Those methods often call for fast implementation and lengthy processes, as well as high sensitivity and reliable instrumentation. This paper explains how your ICP-MS, ICP-OES, and LC-MS-MS workflows can be optimized for compliance with the latest requirements for water testing set by regulations like US EPA methods 200.8, 6010, 6020, and 537.1, along with ISO 17294-2. It will discuss the challenges faced by regulatory labs to meet requirements and present field-proven tips and tricks for simplified implementation and maximized uptime.
